Reports Q3 revenue $2.51B, consensus $2.41B. Worldwide procedures grew approximately 20% compared with the third quarter of 2024. Da Vinci procedures grew approximately 19% and Ion procedures grew approximately 52%. “We’re pleased with our strong results this quarter, underscored by continued growth in customer use and adoption of our Ion and da Vinci platforms, including da Vinci 5,” said Dave Rosa, Intuitive CEO. “We remain focused on helping our customers achieve the Quintuple Aim: delivering better patient care, improving patient and care team experiences, expanding access to high quality care, and reducing overall care costs.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical options imply 6.9% move in share price post-earnings
- Intuitive Surgical: Strong 2024 Performance and New Product Launches Reinforce Buy Rating
- ISRG Earnings this Week: How Will it Perform?
- Analysts See AMD Stock as a Buying Opportunity — Here’s How to Buy Without the Risk
- Intuitive Surgical price target lowered to $525 from $600 at Truist